DIO Valuation

Is A039840 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A039840 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A039840 (₩15960) is trading above our estimate of fair value (₩2632.91)

Significantly Below Fair Value: A039840 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A039840?

Other financial metrics that can be useful for relative valuation.

A039840 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.2x
Enterprise Value/EBITDA-7.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does A039840's PS Ratio compare to its peers?

The above table shows the PS ratio for A039840 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.1x
A150840 IntroMedic
27.9xn/a₩223.7b
A100120 Vieworks
0.9x10.2%₩214.4b
A214680 DRTECH
2.5xn/a₩223.4b
A043150 Value Added Technology
0.9x8.4%₩338.7b
2x14.4%₩239.1b

Price-To-Sales vs Peers: A039840 is expensive based on its Price-To-Sales Ratio (2x) compared to the peer average (1.4x).


Price to Earnings Ratio vs Industry

How does A039840's PE Ratio compare vs other companies in the KR Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.3%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.3%
n/an/an/a
No more companies

Price-To-Sales vs Industry: A039840 is good value based on its Price-To-Sales Ratio (2x) compared to the KR Medical Equipment industry average (2.4x).


Price to Sales Ratio vs Fair Ratio

What is A039840's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A039840 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2x
Fair PS Ratio3.1x

Price-To-Sales vs Fair Ratio: A039840 is good value based on its Price-To-Sales Ratio (2x) compared to the estimated Fair Price-To-Sales Ratio (3.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A039840 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩15,960.00
₩20,600.00
+29.1%
4.1%₩21,800.00₩20,000.00n/a3
Oct ’25₩16,350.00
₩20,600.00
+26.0%
4.1%₩21,800.00₩20,000.00n/a3
Sep ’25₩16,200.00
₩23,600.00
+45.7%
16.5%₩29,000.00₩20,000.00n/a3
Aug ’25₩19,360.00
₩29,500.00
+52.4%
1.7%₩30,000.00₩29,000.00n/a2
Jul ’25₩19,050.00
₩32,000.00
+68.0%
11.1%₩37,000.00₩29,000.00n/a3
Jun ’25₩19,380.00
₩32,000.00
+65.1%
11.1%₩37,000.00₩29,000.00n/a3
May ’25₩20,600.00
₩36,750.00
+78.4%
4.0%₩39,000.00₩35,000.00n/a4
Apr ’25₩22,500.00
₩36,750.00
+63.3%
4.0%₩39,000.00₩35,000.00n/a4
Mar ’25₩21,100.00
₩36,750.00
+74.2%
4.0%₩39,000.00₩35,000.00n/a4
Feb ’25₩19,380.00
₩38,200.00
+97.1%
8.3%₩44,000.00₩35,000.00n/a5
Jan ’25₩22,400.00
₩38,200.00
+70.5%
8.3%₩44,000.00₩35,000.00n/a5
Dec ’24₩21,100.00
₩38,200.00
+81.0%
8.3%₩44,000.00₩35,000.00n/a5
Nov ’24₩23,600.00
₩42,600.00
+80.5%
6.7%₩47,000.00₩39,000.00₩16,290.005
Oct ’24₩25,300.00
₩43,600.00
+72.3%
5.1%₩47,000.00₩40,000.00₩16,350.005
Sep ’24₩29,950.00
₩43,600.00
+45.6%
5.1%₩47,000.00₩40,000.00₩16,200.005
Aug ’24₩31,200.00
₩43,600.00
+39.7%
5.1%₩47,000.00₩40,000.00₩19,360.005
Jul ’24₩33,950.00
₩43,333.33
+27.6%
6.6%₩47,000.00₩40,000.00₩19,050.003
Jun ’24₩29,000.00
₩38,250.00
+31.9%
23.9%₩47,000.00₩23,000.00₩19,380.004
May ’24₩29,700.00
₩38,250.00
+28.8%
23.9%₩47,000.00₩23,000.00₩20,600.004
Apr ’24₩24,850.00
₩31,250.00
+25.8%
15.7%₩35,000.00₩23,000.00₩22,500.004
Mar ’24₩24,400.00
₩33,000.00
+35.2%
17.0%₩40,000.00₩23,000.00₩21,100.005
Feb ’24₩21,850.00
₩34,500.00
+57.9%
20.1%₩40,000.00₩23,000.00₩19,380.004
Jan ’24₩19,700.00
₩34,500.00
+75.1%
20.1%₩40,000.00₩23,000.00₩22,400.004
Dec ’23₩19,600.00
₩34,500.00
+76.0%
20.1%₩40,000.00₩23,000.00₩21,100.004
Nov ’23₩19,800.00
₩38,333.33
+93.6%
6.1%₩40,000.00₩35,000.00₩23,600.003

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies